Fundamental Pharma GmbH has disclosed TRPM4/NMDA 2B (GluN2B) interaction inhibitors potentially useful for the treatment of amyotrophic lateral sclerosis, glaucoma, major depression, postpartum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results